Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients

NCT02558816 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02558816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02558816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients
Lead sponsor
Nantes University Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
October 14, 2015
Completion date
May 13, 2025
Enrollment
48 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma